Life Tech (LIFE) Announces Acquisition of BAC BV; Terms Not Disclosed

January 22, 2013 8:09 AM EST Send to a Friend
Life Technologies Corporation (NASDAQ: LIFE) announced its acquisition of BAC BV, a privately held company based in the Netherlands, and a leader in the discovery, development and manufacture of protein purification products. The acquisition expands Life's capabilities and product offerings in the growing market of biopharmaceutical research and manufacturing.

Bioprocessing is the production and analytical testing of biologically-based therapeutics, which are developed in cultured cells or microorganisms, and include drugs, vaccines, biosimilars, and gene and cell therapies. Life Technologies' Gibco® brand is the market leader in cell culture media, a position it has held for 50 years, and the company more recently integrated its POROS® brand of chromatography resins for purification of therapeutic products into the Bioproduction portfolio.

The acquisition expands Life's existing portfolio by adding BAC BV's unique set of innovative and proprietary affinity ligands to the company's world-class POROS® resins. Affinity ligands are molecules capable of binding with very high affinity to specific proteins, and are typically attached to chromatography resins in a production-scale, bio-purification process.

Life customers will benefit from a streamlined approach to protein purification with tailored end-to-end solutions. In addition to Gibco® culture media, POROS® resins and the BAC BV affinity ligand portfolio for protein purification, Life also offers the Applied Biosystems® SEQ rapid molecular kits for contaminant and impurity testing of bio-therapeutic products.

Financial terms of the deal were not disclosed. The tuck-in acquisition of BAC BV is expected to be neutral to the company's overall ROIC three years after close.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Mergers and Acquisitions

Add Your Comment